Opendata, web and dolomites

MeningoSpeed SIGNED

A unique cost-effective and point of care (PoC) kit for the non-invasive rapid in vitro diagnosis of meningococcal disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MeningoSpeed project word cloud

Explore the words cloud of the MeningoSpeed project. It provides you a very rough idea of what is the project "MeningoSpeed" about.

nanoparticle    acute    neisseria    hospital    solution    tests    specificity    point    source    mainly    successful    diagnostic    first    competitive    disease    patients    cheaper    added    annually    vast    performance    2022    infectious    demonstrated    million    core    meningococcal    physicians    care    finalize    worldwide    business    commercial    reducing    epidemic    profit    abcxwy    tool    public    costly    accumulated    accuracy    sequelae    lack    burden    purchasers    healthcare    children    monitoring    capability    alternatives    least    profitable    cagr    young    france    plan    serogroups    savings    45    spin    caused    company    68    disruptive    treatment    vitro    net    financial    nm    permanent    pcr    people    meningitidis    15    pasteur    diagnosis    tools    feasibility    despite    33    health    launch    25    latex    accurate    societal    lt    immunochromatographic    off    market    projected    secure    meningospeed    gold    gt    md    agglutination    sensitivity    direct    10    deaths    3h    technological    lethality    unmet    min    faster    fashion    opportunity    diseases    biospeedia    ca    valued    rapid    six    limited    invasive    93    2026    vs   

Project "MeningoSpeed" data sheet

The following table provides information about the project.

Coordinator
BIOSPEEDIA 

Organization address
address: INSTITUT PASTEUR - 25 RUE DU DOCTEUR ROUX
city: PARIS
postcode: 75724
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.biospeedia.com/index.php/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOSPEEDIA FR (PARIS) coordinator 50˙000.00

Map

 Project objective

Meningococcal disease (MD), caused by Neisseria meningitidis serogroups (mainly ABCXWY), annually affects 1.2 million people worldwide (mainly children and young). Due to its high lethality (8-15% treated patients), permanent sequelae and epidemic potential, MD represents a major public health problem. Despite the societal burden, there is a lack of rapid and accurate diagnostic tools for timely and early treatment that results very costly for healthcare systems (e.g. direct costs valued in € 68 m/hospital/year). In response to the unmet need, BioSpeedia (spin-off from the Institute Pasteur, France) has vast experience in infectious diseases management and is developing the first-ever gold nanoparticle-based immunochromatographic test with demonstrated diagnostic capability for the six Nm serogroups. MeningoSpeed is a non-invasive, accurate (sensitivity and specificity >93%), rapid (<15 min vs PCR: 3h) and cost-competitive in vitro diagnostic test (€45 sample, at least 25 % cheaper than latex agglutination tests and PCR alternatives) for MD diagnosis. Our one-step solution will result on added value for patients, physicians and healthcare purchasers by improving disease monitoring in an accurate and timely fashion way, reducing deaths and sequelae. MeningoSpeed will provide healthcare systems with limited resources with a reliable and cost-effective diagnostic tool, leading to significant cost-savings. MeningoSpeed´s high accuracy and performance under a faster and cheaper cost make it a disruptive solution with great potential for commercial success in the growing point-of-care market (€33 B by 2022, CAGR 10%). Thus, MeningoSpeed is projected to be a profitable business opportunity and a core source of growth for the company (ca. €33 M of accumulated net profit during 2022-2026). A next feasibility study covering the technological, commercial and financial issues will enable us to finalize our business plan and secure our steps towards the successful market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MENINGOSPEED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MENINGOSPEED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More